Salomon Batina Agasa

Salomon Batina Agasa


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
STSerge Tonen-Wolyec
Serge Tonen-Wolyec
RDRaphaël Dupont
Raphaël Dupont
NANatalio Awaida
Natalio Awaida
SASalomon Batina Agasa
Salomon Batina Agasa
MHMarie-Pierre Hayette
Marie-Pierre Hayette
LBLaurent Bélec
Laurent Bélec
Due to their ease-of-use, lateral flow assay SARS-CoV-2 antigen-detecting rapid diagnostic tests could be suitable candidates for antigen-detecting rapid diagnostic self-test (Ag-RDST). We evaluated the practicability of the Ag-RDST BIOSYNEX Antigen Self-Test COVID-19 Ag+ (Biosynex Swiss SA, Freiburg, Switzerland), using self-collected nasal secretions from the turbinate medium (NMT), in 106 prospectively included adult volunteers living in Paris, France. The majority of the participants correctly understood the instructions for use (94.4%; 95% confidence interval (CI): 88.3–97.4), showing a great ability to perform the entire self-test procedure to obtain a valid and interpretable result (100%; 95% CI: 96.5–100), and demonstrated the ability to correctly interpret test results (96.2%; 95% CI: 94.2–97.5) with a high level of general satisfaction. About one in eight participants (# 15%) needed verbal help to perform or interpret the test, and only 3.8% of test results were misinterpreted. By reference to multiplex real-time RT-PCR, the Ag-RDST showed 90.9% and 100% sensitivity and specificity, respectively, and high agreement (98.1%), reliability (0.94), and accuracy (90.9%) to detect SARS-CoV-2 antigen. Taken together, our study demonstrates the high usability and accuracy of BIOSYNEX Antigen Self-Test COVID-19 Ag+ for supervised self-collected NMT sampling in an unselected adult population living in France.

15 April 2025 in Molecules
Verified
Journal Article
Open access
PDF file
BMBORIVE Amani Marguerite
BORIVE Amani Marguerite
Michel FREDERICHMichel FREDERICH
Michel FREDERICH
OJOlivia Jansen
Olivia Jansen
OBOlivier Bonnet
Olivier Bonnet
ALAllison Ledoux
Allison Ledoux
RDRoland MARINI DJANG'EING'A
Roland MARINI DJANG'EING'A
Sickle cell disease (SCD) is a neglected tropical disease (NTD) associated with severe health consequences, including death. Hibiscus tiliaceus L., from the Malvaceae family, is used traditionally in Kisangani, Democratic Republic of the Congo (DRC), to alleviate symptoms of SCD. However, the specific phytochemicals responsible for the observed therapeutic effects remain unclear. This study aims to characterize the aqueous leaf extract of H. tiliaceus and assess its biological activity against sickle cell disease, including its antisickling, antioxidant, and anti-inflammatory effects. Using techniques such as TLC, HPLC-UV/DAD, LC-MS, and NMR, we identified kaempferol 3-O-rutinoside and rutin in the aqueous extract of H. tiliaceus leaves. Rutin exhibited potent antioxidant and anti-inflammatory activities, with IC50 values of 5 µg/mL and 2.5 µg/mL, respectively. Conversely, kaempferol 3-O-rutinoside demonstrated superior antisickling activity, normalizing sickled red blood cells with an IC50 < 12.5 µg/mL. Due to the pathophysiology of SCD, which involves the polymerization of red blood cells, which induces oxidative stress and an inflammatory response, this study suggests the importance of H. tiliaceus for the management of SCD. Additionally, the combined effect of molecules in H. tiliaceus will help in normalizing erythrocytes, inhibiting free radicals generated by early hemolysis, thus contributing to inflammatory processes reduction. This finding provides evidence and validates the traditional use of H. tiliaceus aqueous extract for the management of SCD.

10 January 2017 in International Blood Research & Reviews
Verified
Journal Article
Open access
PDF file
SASalomon Batina Agasa
Salomon Batina Agasa
MBMbutu Mango Bernard
Mbutu Mango Bernard
BLBolukaoto Bome Lucien
Bolukaoto Bome Lucien
OJOssinga Basandja Jacques
Ossinga Basandja Jacques
KPKambale Kombi Paul
Kambale Kombi Paul
KCKayembe Tshilumba Charles
Kayembe Tshilumba Charles
Background and Aims: To know blood group antigen frequencies in a population has various benefits as the assessing risk of alloimmunization, the providing antigen-negative compatible blood to patients with multiples antibodies and the development of a donor data bank for the preparation of indigenous cell panels. The aims of this study is to determine the frequencies of the ABO, Rh and Kell antigens in the blood donors in Kisangani, in the northeast region of Democratic Republic of Congo. Materials and Methods: Blood samples from 252 volunteer blood donors coming to the Blood Transfusion Provincial Center at Kisangani in 2015 were typed by serologic test for ABO, Rh (D, C, E, c, e) and K antigens. Results: For the 252 blood donors, the most frequent phenotype in the ABO blood group, was O (47.6%) followed by A (30.6%), B (17.1%) and AB (4.1%). If combined ABO and Rh blood groups, O positive was most frequent, followed by A positive, B positive, AB positive, O negative and A negative respectively. In the Rh system, the c antigen was the most frequent (98.8%), followed by e antigen (97.6%), D antigens (96.42%), C antigen (15.9%) and E antigen (13.9%). Among ten phenotypes identified in the Rh system, the phenotype R0r was the most frequently encountered (71.03%). In the Kell system, 100% of donors were K-k+. Conclusion: Although the Africa specificities for the most immunogenic antigens and the context of limited resources, it is important for better care of patients to improve tests as phenotyping red cells.

2 July 2026 in Diseases
Verified
Journal Article
Open access
PDF file
AKAlex Liripa Kwendra
Alex Liripa Kwendra
Augustin MOUINGA ONDEMEAugustin MOUINGA ONDEME
Augustin MOUINGA ONDEME
JEJéordy Dimitri Engone-Ondo
Jéordy Dimitri Engone-Ondo
RTRoger Buju Tsedha
Roger Buju Tsedha
JNJustin Byaruhanga Ngona
Justin Byaruhanga Ngona
ZKZacharie Tsongo Kibendelwa
Zacharie Tsongo Kibendelwa
Background: The fight against HIV in the Democratic Republic of Congo (DRC) is hindered by systemic challenges; notably, limited access to HIV viral load (VL) testing. Achieving VL suppression is the primary global target for eliminating HIV as a public health threat by 2030. This study aimed to determine the rate of VL suppression and identify associated factors among people living with HIV (PLHIV) receiving antiretroviral therapy (ART) in Bunia. Methods: A descriptive and analytical cross-sectional study was conducted among PLHIV receiving care at treatment sites in Bunia over a period of 11 months. Participants were selected using a two-stage sampling approach, consisting of non-random quota sampling followed by simple random sampling. The primary endpoint was the proportion of PLHIV achieving VL suppression, while associated factors were identified using multiple logistic regression analysis. Results: Overall, 603 PLHIV were enrolled, including 180 males (29.9%) and 423 females (70.1%). The median age was 40 years (IQR: 32–48), median duration on ART was 38 months (IQR: 15–91), and VL suppression was achieved by 75% of the participants. While this indicates significant progress, it remains below the UNAIDS 95-95-95 targets. Adherence to antiretroviral therapy (aOR = 139.43; 95% CI: 66.63–291.76; p < 0.001) and being female (aOR = 2.15; 95% CI: 1.02–4.53; p = 0.044) emerged as independent predictors of virological success. Conclusions: Enhancing access to VL testing and optimizing ART adherence support strategies are critical to improving VL suppression rates in Bunia. Addressing these gaps is essential for the DRC to align with the global health objectives.

25 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BMBORIVE Amani Marguerite
BORIVE Amani Marguerite
HMHélène Mavar Manga
Hélène Mavar Manga
AMAnge Mouithys-Mickalad
Ange Mouithys-Mickalad
EBElodie Nsasi Bakiantima
Elodie Nsasi Bakiantima
RARachel Ndezu Angirio
Rachel Ndezu Angirio
RDRoland MARINI DJANG'EING'A
Roland MARINI DJANG'EING'A
Our study explored the scientific rationale behind the traditional use of medicinal plants as a foundation for evidence-based strategies for the management of sickle cell disease (SCD) in developing countries. Firstly, we conducted a survey among people living at Kisangani city in DR Congo to identify the plants used alone or in combination for the SCD management considering the following criteria: used parts, preparation methods, administration routes and common combinations with other substances. This step allowed to select the most used plants which were harvested from two different soil types and prepared according to local practices. Secondly, different preparations were tested at laboratory focusing on the antioxidant and anti-inflammatory biological activities which are mainly observed with people suffering from SCD. Out of 384 surveyed people, 201 reported the use of 45 medicinal plants whereas the additives comprised sugar, caramel, ash and lemon juice. Alchornea cordifolia Müll. Arg and Hibiscus tiliaceus L. were selected for laboratory analyses. Their leaves were collected from both dry and marshy soils and prepared following local methods with additive. A. cordifolia showed significantly higher antioxidant (p = 0.001) and anti-inflammatory activity (p = 0.01) than H. tiliaceus. Soil type influenced activity in H. tiliaceus, favoring marshy soil. However, sugar and caramel significantly reduced bioactivity, ash and lemon juice enhanced antioxidant effects without significantly altering anti-inflammatory properties.

Verified
Journal Article
Open access
PDF file
AKAlex Liripa Kwendra
Alex Liripa Kwendra
Augustin MOUINGA ONDEMEAugustin MOUINGA ONDEME
Augustin MOUINGA ONDEME
JEJéordy Dimitri Engone-Ondo
Jéordy Dimitri Engone-Ondo
CHCHELO NGADJOLE Herman
CHELO NGADJOLE Herman
OAOtniel Adjala-Ondeme
Otniel Adjala-Ondeme
IMIvan S. Mfouo-Tynga
Ivan S. Mfouo-Tynga
The adoption and widespread use of dolutegravir (DTG)-based antiretroviral therapy (ART) are key strategies for achieving global 2030 targets, though emerging resistance threatens long-term success. This study evaluated HIV-1 drug resistance mutations among participants experiencing virological failure in Bunia, Democratic Republic of the Congo (DRC). Over an 11-month period, a prospective cohort study was conducted across 20 healthcare facilities in Bunia, Ituri Province. Targeted genotyping of the HIV-1 pol gene was performed, antiretroviral resistance mutations were identified, and genotypic sensitivity scores (GSSs) were calculated using the Stanford HIV Drug Resistance Database. Virological failure occurred in 12.3% (74/603) of participants, and targeted genotyping of the HIV-1 pol gene was attempted on 53 samples. This subgroup comprised 41 females (55.4%) and 33 males (44.6%), with a median age of 36 years (IQR: 17.0) and a median ART duration of 24 months. Subsubtype A1 predominated (38%), followed by subtypes G (26%) and D (9%); recombinant forms, led by CRF02_AG, accounted for 16%. Mutations associated with resistance to reverse transcriptase inhibitors were detected in 26.4% (14/53) of successfully sequenced samples, compared with 33.9% (18/53) for integrase strand-transfer inhibitors. Overall, GSS analysis revealed that 98% (50/51) of evaluable participants scored 3, whereas only 2% (1/51) scored below 3. This study demonstrates that DTG-based ART remains highly effective in Bunia. To optimize treatment outcomes and support progress toward the UNAIDS 95-95-95 targets, targeted interventions to enhance treatment adherence are urgently warranted.